Table 1.
Selected Characteristics of Population-based Prostate Cancer Cases and Controls in King County, Washington, 2002–2005
Characteristic | Cases (n = 1,001) |
Controls (n = 942) |
Odds Ratioa | 95% CI | ||
No. | % | No. | % | |||
Age, years, at reference date | ||||||
35–49 | 93 | 9.3 | 96 | 10.2 | ||
50–54 | 108 | 10.8 | 113 | 12.0 | ||
55–59 | 184 | 18.4 | 174 | 18.5 | ||
60–64 | 218 | 21.8 | 187 | 19.9 | ||
65–69 | 210 | 21.0 | 202 | 21.4 | ||
70–74 | 188 | 18.8 | 170 | 18.0 | ||
Race | ||||||
Caucasian | 843 | 84.2 | 844 | 89.6 | 1.00 | Referent |
African American | 158 | 15.8 | 98 | 10.4 | 1.69 | 1.29, 2.23 |
First-degree family history of prostate cancer | ||||||
No | 775 | 77.4 | 833 | 88.4 | 1.00 | Referent |
Yes | 226 | 22.6 | 109 | 11.6 | 2.25 | 1.75, 2.89 |
Annual income, $ | ||||||
<15,000 | 48 | 5.0 | 47 | 5.1 | 0.86 | 0.56, 1.34 |
15,000–29,999 | 85 | 8.9 | 93 | 10.1 | 0.77 | 0.54, 1.08 |
30,000–49,999 | 189 | 19.7 | 169 | 18.4 | 0.95 | 0.72, 1.25 |
50,000–74,999 | 212 | 22.1 | 206 | 22.5 | 0.88 | 0.68, 1.13 |
75,000–99,999 | 141 | 14.7 | 157 | 17.1 | 0.76 | 0.57, 1.02 |
≥100,000 | 284 | 29.6 | 245 | 26.7 | 1.00 | Referent |
Missing | 42 | 25 | ||||
Education | ||||||
≤ High school | 196 | 19.6 | 181 | 19.2 | 1.00 | Referent |
Some college | 241 | 24.1 | 210 | 22.3 | 1.07 | 0.81, 1.40 |
College degree | 262 | 26.2 | 261 | 27.7 | 0.94 | 0.72, 1.22 |
Graduate degree | 301 | 30.1 | 289 | 30.7 | 0.97 | 0.75, 1.25 |
Body mass index, kg/m2 | ||||||
<25 | 287 | 28.7 | 259 | 27.5 | 1.00 | 0.81, 1.24 |
25.0–29.9 | 492 | 49.2 | 444 | 47.1 | 1.00 | Referent |
30.0–34.9 | 168 | 16.8 | 186 | 19.8 | 0.81 | 0.64, 1.04 |
≥35.0 | 54 | 5.4 | 53 | 5.6 | 0.91 | 0.61, 1.36 |
Recent exercise, times/weekb | ||||||
None | 262 | 26.2 | 246 | 26.1 | 1.00 | Referent |
1–2 | 315 | 31.5 | 283 | 30.0 | 1.05 | 0.83, 1.33 |
3–4 | 251 | 25.1 | 244 | 25.9 | 0.97 | 0.76, 1.25 |
≥5 | 173 | 17.3 | 169 | 17.9 | 0.96 | 0.73, 1.27 |
Smoking status | ||||||
Nonsmoker | 428 | 42.8 | 429 | 45.6 | 1.00 | Referent |
Former smoker | 462 | 46.2 | 394 | 41.9 | 0.94 | 0.70, 1.26 |
Current smoker | 111 | 11.1 | 118 | 12.5 | 1.16 | 0.96, 1.41 |
Prostate cancer screeningc | ||||||
None | 133 | 13.3 | 136 | 14.4 | 1.00 | Referent |
Digital rectal examination only | 159 | 15.9 | 263 | 27.9 | 0.62 | 0.46, 0.85 |
PSA test | 709 | 70.8 | 543 | 57.6 | 1.36 | 1.04, 1.78 |
Migraines | ||||||
Never | 929 | 92.8 | 876 | 93.2 | 1.00 | Referent |
Ever | 72 | 7.2 | 64 | 6.8 | 1.06 | 0.74, 1.50 |
Arthritis (rheumatoid or osteoarthritis) | ||||||
Never | 833 | 84.2 | 767 | 82.3 | 1.00 | Referent |
Ever | 156 | 15.8 | 165 | 17.7 | 0.86 | 0.68, 1.10 |
Gastroesophageal reflux disease | ||||||
Never | 819 | 81.9 | 759 | 80.7 | 1.00 | Referent |
Ever | 181 | 18.1 | 181 | 19.3 | 0.92 | 0.73, 1.16 |
Gastrointestinal ulcer | ||||||
Never | 886 | 88.5 | 855 | 91.1 | 1.00 | Referent |
Ever | 114 | 11.4 | 84 | 8.9 | 1.29 | 0.96, 1.74 |
Heart attack | ||||||
Never | 932 | 93.2 | 862 | 91.5 | 1.00 | Referent |
Ever | 68 | 6.8 | 80 | 8.5 | 0.76 | 0.54, 1.08 |
Stroke | ||||||
Never | 968 | 96.7 | 907 | 96.6 | 1.00 | Referent |
Ever | 32 | 3.2 | 32 | 3.4 | 0.93 | 0.57, 1.53 |
Gleason score | ||||||
3–4 | 7 | 0.7 | ||||
5–6 | 518 | 52.0 | ||||
7 (3 + 4) | 294 | 29.5 | ||||
7 (4 + 3) | 78 | 7.8 | ||||
8–10 | 99 | 9.9 | ||||
Missing | 5 | |||||
Stage of cancer | ||||||
Local | 819 | 81.8 | ||||
Regional | 160 | 16.0 | ||||
Distant | 22 | 2.2 | ||||
PSA value, ng/mLd | ||||||
<4.0 | 134 | 14.3 | 720 | 91.6 | ||
4.0–9.9 | 592 | 63.1 | 55 | 7.0 | ||
10.0–19.9 | 143 | 15.2 | 10 | 1.3 | ||
≥20.0 | 69 | 7.4 | 1 | 0.1 | ||
Missing | 63 | 156 | ||||
Prostate cancer aggressivenesse | ||||||
Less aggressive | 686 | 68.5 | ||||
More aggressive | 315 | 31.5 |
Abbreviation: CI, confidence interval; PSA, prostate-specific antigen.
Adjusted for age at reference date.
Exercise frequency 1 year before reference date.
Prostate cancer within 5 years before reference date.
Measured at diagnosis for cases and at interview for controls.
Less aggressive = Gleason ≤7 (3 + 4), local stage, and PSA <20 ng/mL; more aggressive = Gleason ≥7 (4 + 3) or regional/distant stage or PSA ≥20 ng/mL.